» Articles » PMID: 39247675

Atrial Fibrillation in Hypertrophic Cardiomyopathy

Overview
Journal JACC Adv
Date 2024 Sep 9
PMID 39247675
Authors
Affiliations
Soon will be listed here.
Abstract

Atrial fibrillation (AF) is common among patients with hypertrophic cardiomyopathy (HCM) with a prevalence greater than 25%. AF in HCM is associated with a high risk of stroke and can be a marker of more advanced cardiomyopathy. Although, it frequently results in cardiac hemodynamic changes which are poorly tolerated, it can be subclinical. Thus, prompt diagnosis and adequate management of AF are essential to minimizing AF-related adverse outcomes in HCM. All HCM patients should be screened for AF regularly, and those with high-risk features should be screened more frequently preferably with extended ambulatory monitoring. Once AF is detected, oral anticoagulation should be initiated. Both general and HCM-specific modifiable risk factors should be addressed and assessment for cardiomyopathy progression should be performed. Although no randomized controlled studies have compared rate versus rhythm control in HCM, early rhythm control could be considered to prevent further LA remodeling.

Citing Articles

What the blood knows: predicting atrial fibrillation risk in hypertrophic cardiomyopathy patients.

Jabbour G, Tadros R, Remme C Europace. 2024; 26(11).

PMID: 39441041 PMC: 11542481. DOI: 10.1093/europace/euae268.

References
1.
Eleid M, Konecny T, Orban M, Sengupta P, Somers V, Parish J . High prevalence of abnormal nocturnal oximetry in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009; 54(19):1805-9. DOI: 10.1016/j.jacc.2009.07.030. View

2.
Aglan A, Fath A, Maron B, Maron M, Prasad A, Almomani A . Percutaneous left atrial appendage closure for stroke prevention in hypertrophic cardiomyopathy patients with atrial fibrillation. Heart Rhythm. 2024; 21(9):1677-1683. DOI: 10.1016/j.hrthm.2024.05.038. View

3.
Zahid S, Malik T, Peterson C, Tarabanis C, Dai M, Katz M . Conduction velocity is reduced in the posterior wall of hypertrophic cardiomyopathy patients with normal bipolar voltage undergoing ablation for paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2023; 67(1):203-210. DOI: 10.1007/s10840-023-01533-9. View

4.
Coppini R, Ferrantini C, Pioner J, Santini L, Wang Z, Palandri C . Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study. JACC Basic Transl Sci. 2020; 4(7):795-813. PMC: 6978554. DOI: 10.1016/j.jacbts.2019.06.004. View

5.
Cheung M, Husain A, Du D, Li C, Parker J, Weissler-Snir A . International Practice Patterns in the Detection and Management of Arrhythmias in Patients With Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2022; 11(19):e027385. PMC: 9673716. DOI: 10.1161/JAHA.122.027385. View